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In an initial study, we compared quantitative transcriptome data across mouse brain territories using the serial analysis of gene expression
method. Among the novel regional markers that we discovered, we focused on a striatum-enriched transcript with no available experimental
cDNA sequence. Here, we report its cloning, gene structure, and detailed distribution in mouse brain. Quantitative RT-PCR and in situ
hybridization demonstrated predominant expression in dorsolateral striatum. We therefore named it capucin for caudate-and putamen-enriched
sequence. Mouse capucin is a 237-amino-acid protein, without any registered ortholog in mammalian species. It contains no recognizable motif
other than two predicted carboxy-terminal transmembrane domains. When expressed in fusion with a fluorescent protein, it localized to the Golgi
apparatus in two mammalian cell lines. Interestingly, we observed a significant down-regulation of capucin mRNA levels in two rodent models of
Huntington disease, indicating a possible contribution to the pathogenesis of this disorder.
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Huntington disease
To perform highly integrated tasks, the mammalian brain nergic neurons results in dopamine depletion in the striatumrelies on a complex network architecture involving specialized
anatomical structures. Assuming that functional specificity is
determined by the expression of unique sets of genes,
transcriptome analysis of brain regions could provide valuable
information on their physiology. The striatum, a basal ganglion
participating in the control of movement, is particularly suited
to such global-scale approaches. First, it is specifically
involved in several neurodegenerative conditions. Severe
atrophy of the striatum, due to the selective loss of medium
spiny neurons, is a characteristic feature of Huntington disease
[1]. In Parkinson disease, the degeneration of nigral dopami-0888-7543/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
doi:10.1016/j.ygeno.2005.10.009
i Sequence data from this article have been deposited with the GenBank
Data Library under Accession Nos. AY993932–AY993934. The approved
nomenclature for capucin is transmembrane protein 90a (Tmem90a).
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E-mail addresses: chaldee@dsvidf.cea.fr (M. de Chalde´e),
jean-marc.elalouf@cea.fr (J.M. Elalouf).[2]. Furthermore, a number of psychoactive drugs target striatal
dopaminergic synapses. For instance, cocaine and amphet-
amine increase dopaminergic activity through the impairment
of dopamine transporter function [3–5], while most antipsy-
chotics reduce the efficiency of dopamine neurotransmission
by blocking D2 receptors [6]. Second, the cell composition of
the striatum is not as complex as that of many other brain
regions [2]. Finally, the striatum is easily accessible to
experimentation. Even in small animals such as mice, it
appears as a massive structure with distinctive anatomical
features and well-defined boundaries [7].
Most global analyses of gene expression in the striatum
have been carried out in animal models of Huntington disease
[8], Parkinson disease [9,10], and addiction [11]. Studies
designed to find constitutive striatal markers are sparser. In an
early publication, nine independent cDNAs were cloned from a
rat striatum library from which cerebellar cDNAs had been
subtracted. Subsequent investigation of other brain regions6) 200 – 207
www.el
M. de Chalde´e et al. / Genomics 87 (2006) 200–207 201demonstrated the enrichment of the corresponding transcripts
in the striatum [12]. Among them, one was further character-
ized as Rasd2 (originally named Rhes), a Ras-related small
GTP-binding protein up-regulated by thyroid hormone during
postnatal brain maturation [13–15]. More recently, differential
display of RNA from seven rat brain regions led to the isolation
of Gpr88, a striatum-specific orphan G-protein-coupled recep-
tor whose sequence and expression pattern are conserved in
human and mouse [16].
To discover novel constitutive markers of the striatum,
we have generated quantitative expression data on a global
scale for various mouse brain territories [17]. For this
purpose, we used the serial analysis of gene expression
(SAGE) method, which offers the opportunity to detect new
or poorly characterized transcripts [18]. We then compared
SAGE data between the striatum and other brain regions
and drew up a list of striatum-enriched transcripts, a number
of which had never been described before [17]. In the
present paper, we report the cDNA cloning and gene
structure of one of these novel markers and provide a
detailed analysis of its expression pattern in wild-type
mouse brain. It was originally termed striatal marker 20
(StM20), but will be henceforth referred to as capucin for
caudate-and putamen-enriched sequence. As a first step
toward the characterization of the corresponding protein,
we present results from homology searches and heterologous
expression experiments. Finally, to investigate the possible
role of capucin in striatal pathophysiology, we measured its
mRNA levels in two rodent models of Huntington disease.
Results
cDNA cloning and gene structure of capucin
We initially identified capucin as a striatum-enriched
mRNA species (StM20) in a SAGE analysis of wild-type
mouse brain regions [17]. The principle of this method is to
sequence one 10-bp-long tag from each molecule of an
oligo(dT)-primed cDNA library [18]. The main SAGE tag
(tag 1) corresponding to capucin matches UniGene cluster
Mm.152484. We therefore designed an antisense oligonu-Fig. 1. Organization of the capucin gene. Exons are shown as boxes. Black filling ind
shows the location of the probe used for Northern hybridization and cDNA cloning. T
ESTs of UniGene cluster Mm.152484.cleotide probe in the vicinity of tag 1 within this cluster
(Fig. 1) and hybridized it to a mouse poly(A)+RNA
Northern blot. Two transcripts of approximately 2.7 and
2.8 kb, with comparable abundance, were detected in the
whole brain [17].
Since cluster Mm.152484 contains no experimental full-
length cDNA, we constructed an oligo(dT)-primed cDNA
library from mouse striatum and screened it with the probe
used for Northern hybridization. We obtained two cDNAs that
differ in the presence or absence of a 102-bp-long sequence,
which is consistent with the Northern results. We deposited the
corresponding sequences in GenBank under Accession Nos.
AY993933 (long variant) and AY993934 (short variant). Both
of them contain the same open reading frame, which starts with
an ATG codon in an adequate context [19] and encodes a
protein of 237 amino acid residues.
Although containing the full predicted coding sequence,
these cDNAs are almost 1 kb shorter than expected from the
Northern data. Minute analysis of the striatum SAGE libraries
identified a tag (tag 2) matching sequences located 3V of
AY993933 and AY993934, but still clustering in Mm.152484.
We thus assume that capucin transcripts encompass the cDNAs
that we cloned and more 3V ESTs, yielding molecules of the
expected size (Fig. 1). The underrepresentation of distal 3V
sequences is probably due to oligo(dT) primer hybridization to
a 27-base-long A stretch located between SAGE tags 1 and 2.
The capucin gene spans 21.6 kb on mouse chromosome
12 (12D1). Seventy percent of its length is accounted for by
the first intron. The gene comprises five exons, of which the
first two are not translated. The difference between
AY993933 and AY993934 is explained by the alternative
skipping of exon 2 (Fig. 1). A gene model (Gm261, predicted
cDNA sequence XM_138094) has been associated with
cluster Mm.152484. It predicts an additional 207-bp-long
coding exon between exons 3 and 4. However, the actual
existence of this putative exon is not supported by our
findings nor any mouse transcribed sequence deposited in
GenBank.
We screened the mouse striatum cDNA library for
another striatum-enriched transcript originally detected by
SAGE and designated as StM6 for striatal marker 6 [17].icates the coding sequence. Tag 1 and tag 2 refer to the SAGE data. The asterisk
he 5V end of the first exon and the 3V end of the last exon were determined from
Fig. 2. Capucin mRNA levels in mouse brain regions assessed by real-time quantitative RT-PCR. The expression level is expressed as a percentage of that obtained in
caudate–putamen, where expression is maximal.
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protein of 580-amino-acid residues (GenBank Accession No.
AY993932). This protein is the mouse ortholog of a recently
characterized rat sequence, referred to as protein phosphatase 1
and actin interactor Phactr1 [20].
Detailed analysis of capucin expression pattern
In a first approach, we used real-time quantitative RT-PCR
to assess the expression of capucin in a total of 13 territories
sampled from the forebrain (cortical areas, hippocampus,
striatum, and thalamus), midbrain (substantia nigra and ventral
tegmental area), and hind brain (cerebellum) of wild-type mice.
The striatum was divided into a dorsal (caudate–putamen) and
a ventromedial part (nucleus accumbens). The whole brain wasFig. 3. Capucin mRNAs visualized by in situ hybridization to mouse brain coronal s
Acb, nucleus accumbens; CPu, caudate–putamen, Tu, olfactory tubercle). (B) Vent
layer; GrO, granular cell layer; IPl, internal plexiform layer; Mi, mitral cell layer)
mediodorsal thalamic nucleus; MHb, medial habenular nucleus; PV, paraventricular
hybridization signals.also included in the analysis to detect any possible prominent
expression in an unsampled region (Fig. 2). Capucin expres-
sion was maximal in the caudate–putamen. It was more than
20 times lower in all other regions investigated, except the
nucleus accumbens, where it was only 2.3 times lower, and the
ventral tegmental area, where it was 6 times lower. Significant
expression in the nucleus accumbens is not surprising, since it
belongs to the striatal complex and shares many architectural
features with the caudate–putamen. Compared to the whole
brain, a 13.5-fold enrichment was observed in the caudate–
putamen, which is consistent with their relative size. Altogeth-
er, these results suggest a very restricted expression pattern of
capucin in mouse brain.
To refine the analysis of capucin mRNA distribution in
mouse fore-and midbrain, we turned to in situ hybridization.ections. (A) Full section 1 mm anterior to the bregma (ac, anterior commissure;
ral striatum. (C) Olfactory bulbs (EPl, external plexiform layer; Gl, glomerular
. (D) Dorsal thalamus and habenula (AD, anterodorsal thalamic nucleus; MD,
thalamic nucleus; sm, stria medullaris of the thalamus). Arrows indicate in situ
Fig. 4. Alignment of capucin with homologous proteins. (A) Alignment of mouse capucin with partial human capucin (TMEM90A) and human TMEM90B
(Q9H7V2). (B) Alignment of the carboxy-termini of mouse capucin and human TMEM90B, TMEM91 (Q6ZNR0), PRRT1 (Q99946), PRRT2 (Q96FA8), and
TUSC5 (Q8IXB3). Black backgrounds indicate identity or conservation with mouse capucin. Predicted transmembrane domains are designated as TM 1 and TM 2.
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marked dorsolateral to ventromedial decreasing gradient
(Fig. 3B). In particular, the signal was much fainter in the
nucleus accumbens and olfactory tubercles than in the
caudate–putamen. Hybridization to other brain sections
revealed the expression of capucin in the shell of the
olfactory glomeruli (Fig. 3C) and in three diencephalicFig. 5. Expression of EYFP–mouse capucin fusion proteins in mammalian cell lin
CHO cells. (B) Expression of mouse capucin fused to the carboxy-terminus of EYFP
to the amino-terminus of EYFP. (D–F) Coexpression of mouse capucin fused to
homolog in HeLa cells. (D) Autofluorescence of EYFP–mouse capucin fusion pr
homolog. (F) Confocal overlay of D and E.nuclei: the anterodorsal nucleus of the thalamus, which was
intensely stained; the paraventricular nucleus of the thala-
mus; and the medial habenular nucleus (Fig. 3D). No signal
was visible in the ventral tegmental area. Capucin expres-
sion is therefore detectable in only a few discrete regions of
mouse brain and is prominent in the dorsolateral part of the
striatum.es. (A) Expression of mouse capucin fused to the amino-terminus of EYFP in
in HeLa cells. (C) Effect of BFA on HeLa cells expressing mouse capucin fused
the amino-terminus of EYFP and hemagglutinin (HA)-tagged human unc-50
otein. (E) Anti-HA immunofluorescent staining of HA-tagged human unc-50
Fig. 6. Capucin, Purkinje cell protein 4, and hippocalcin mRNA levels in
Huntington disease models assessed by real-time quantitative RT-PCR. (A
mRNA levels in the striata of 6-week-old R6/2 mice relative to wild-type
controls. (B) mRNA levels in 8-week-old mutant-infected cultures of ra
striatum relative to control-infected cultures. mRNA levels are expressed as a
percentage of the appropriate control T SEM (Pcp4, Purkinje cell protein 4
Hpca, hippocalcin). Asterisks denote significance thresholds as determined by
unpaired Student_s t test (*p < 0.01; **p < 0.001).
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To identify human and rat orthologs of the mouse
capucin gene, we aligned mouse capucin cDNAs with all
human and rat transcribed sequences deposited in GenBank.
In human, we could reconstruct a partial coding sequence
from UniGene cluster Hs.12400 and EST DN831347. The
corresponding partial protein (TMEM90A, 176 amino acid
residues) is 89% identical to mouse capucin (Fig. 4A). In
rat, all the available transcribed sequences matching capucin
are located in the 3V-UTR of the gene.
We then searched the UniProt database for proteins
sharing sequence homologies with mouse capucin. The
transmembrane protein 90B (TMEM90B), a human protein
of unknown function, shows a high degree of conservation
(59%) with capucin (Fig. 4A). All other homologies are
concentrated within the last 90 carboxy-terminal residues of
the proteins (Fig. 4B). This region relates capucin to two
Pfam families: Pfam-B_16429, in which the best capucin
homologs are clustered (TMEM90B, TMEM91, and PRRT1,
all uncharacterized), and the CD225 family, named after a
human interferon-inducible leukocyte antigen (interferon-
induced transmembrane protein 1), to which more distant
homologs belong (PRRT2 and TUSC5, synonym of LOST1,
a tumor suppressor candidate in lung cancer [21]). The
conserved region contains two putative transmembrane
domains (Fig. 4B). No other motif was predicted for
capucin.
Subcellular localization of EYFP–mouse capucin fusion
proteins in two mammalian cell lines
To address the subcellular localization of capucin, we
transiently expressed the mouse protein fused to the
enhanced yellow fluorescent protein (EYFP) in CHO and
HeLa cells. In both cell lines, and irrespective of whether
capucin was fused to the amino-or carboxy-terminus of
EYFP, we observed a compact juxtanuclear fluorescence in
transfected cells (Figs. 5A, 5B, and 5D), reminiscent of the
Golgi apparatus. The same results were obtained when
EYFP was replaced by the Myc epitope, and the fusion
protein was detected by anti-Myc immunofluorescence (data
not shown). To validate the possible Golgi localization of
the fusion proteins, we treated transfected HeLa cells with
brefeldin A (BFA), a fungal metabolite that induces the
redistribution of cis and medial Golgi proteins into the
endoplasmic reticulum (ER) [22]. Upon BFA treatment, a
diffuse reticular pattern of fluorescence characteristic of the
ER was consistently observed (Fig. 5C).
In a second series of experiments, we cotransfected HeLa
cells with mouse capucin and human unc-50 homolog
(alternatively designated as GMH1), a cis-Golgi membrane
protein [23]. Confocal fluorescence microscopic analysis of
anti-HA immunofluorescently labeled cotransfected cells
revealed colocalization of both proteins (Figs. 5D–5F), thus
demonstrating that EYFP–mouse capucin fusion proteins
indeed localize to the cis-Golgi.Capucin expression in two rodent models of Huntington
disease
The genetic basis of Huntington disease consists in an
abnormal expansion of a CAG repeat in the first exon of the
gene encoding the huntingtin protein [24]. Since huntingtin
is ubiquitous, the regional selectivity of the neurodegener-
ative phenotype might be accounted for by striatum-specific
targets or downstream effectors. To investigate the possible
involvement of capucin in the pathogenesis of Huntington
disease, we measured its expression levels in the striata of
6-week-old wild-type and R6/2 transgenic mice using real-
time quantitative RT-PCR. R6/2 mice express a fragment of
the diseased human huntingtin-encoding gene, containing
about 145 CAG repeats, and develop a progressive
neurological phenotype beginning at 2 months of age [25].
Capucin mRNA levels are significantly lower in the striata
of R6/2 mice compared to wild-type controls (Fig. 6A), by
an even greater magnitude than Purkinje cell protein 4 and
hippocalcin, two transcripts previously demonstrated to be
down-regulated in the striata of R6/2 mice [8].
We also tested capucin expression in a cellular model of
Huntington disease, in which primary cultures of rat striatal
neurons are infected with a lentiviral vector encoding the
amino-terminal part of human huntingtin containing either 19
(control) or 82 (mutant) glutamines. The mutant construct has
been shown to induce a progressive pathology specifically
affecting striatal neurons [26]. We used real-time RT-PCR to)
t
;
M. de Chalde´e et al. / Genomics 87 (2006) 200–207 205quantify capucin mRNA levels in 8-week-old cultures of
striatal neurons infected with either the control or the mutant
construct and found a significantly lower expression of capucin
in the mutant-infected cultures (Fig. 6B). Purkinje cell protein
4 was also down-regulated, but interestingly, no change was
observed for hippocalcin. Altogether, our results indicate a
possible role for capucin in the pathogenesis of Huntington
disease.
Discussion
For the purpose of identifying new constitutive markers of
mammalian brain regions, we applied the SAGE method to
mouse microdissected brain territories. This approach proved
successful, as we were able to detect a number of new or poorly
documented transcripts showing a heterogeneous distribution
in mouse brain [17]. Among these, capucin exhibits a strikingly
restricted pattern of expression. Its mRNAs, detectable only in
brain and, to a lesser extent, in testis [17], are essentially
confined to the striatum, making it one of the most specific
known markers for this structure, comparable, for instance, to
protein phosphatase 1 regulatory subunit 1B (usually desig-
nated as dopamine-and cAMP-regulated phosphoprotein
DARPP-32) [27], regulator of G-protein signaling 9 (RGS9)
[28], or D1 dopamine receptor [29]. SAGE further provides
quantitative information on the expression level of each
transcript species detected. Capucin messengers account for
about 0.03% of mouse striatum mRNAs, a level in the same
range as that of RGS9 or D2 dopamine receptor [17].
The present in situ hybridization data show decreasing
amounts of capucin transcripts from dorsolateral to ventrome-
dial regions of the striatal complex. Gradual differences in
connectivity and organization along this axis are abundantly
documented. Dorsolateral parts of the striatum receive afferents
from the sensorimotor cortex, while inputs to the ventromedial
striatum arise from the prefrontal cortex, hippocampus, and
amygdala [7]. This segregation pattern is partly paralleled by
the distribution of neurochemical markers [2]. In addition to the
striatum, which is densely innervated by dopaminergic fibers
originating in the midbrain, capucin mRNAs were detected in
the shell of olfactory glomeruli, the anterodorsal and para-
ventricular nuclei of the thalamus, and the medial habenula.
Interestingly, all these regions have been reported to receive
dopaminergic inputs or express proteins participating in
dopaminergic transmission. In the olfactory bulb, a large
proportion of periglomerular interneurons synthesize dopamine
[30]. Accordingly, high levels of D2 dopamine receptor
mRNAs and binding sites have been observed in the
glomerular layer [31]. The anterodorsal nucleus is part of the
so-called limbic thalamus, which relays information from the
hippocampal formation to the retrosplenial cortex. D1 dopa-
mine receptor mRNAs have been detected in this nucleus [29].
As a midline thalamic nucleus, the paraventricular nucleus
receives a complex set of afferents and projects to the striatum
and prefrontal cortex. Dopaminergic inputs from the midbrain
have been demonstrated in both this nucleus and the habenula
[32]. The latter structure links the limbic forebrain to midbrainnuclei. It has been involved in a series of biological and
behavioral functions. Remarkably, significant expression of
DARPP-32 has been reported in the medial habenula [27].
As it does not depend on the availability of sequence
information, the SAGE method is a powerful approach to the
discovery of novel transcripts. Before the present study, no
experimental cDNA corresponding to capucin had been
deposited in public databases. Capucin is closely related to a
putative human protein, TMEM90B. Its amino-terminal two-
thirds does not contain any known functional domains, but
remote homologies with the family of interferon-induced
transmembrane proteins (IFITMs) can be detected in its
carboxy-terminus. IFITM1 (Leu-13) is the best characterized
member in this family. On the cell surface of B and L
lymphocytes, it is associated with other membrane proteins to
form a multimeric complex, which, upon antibody binding,
inhibits cell proliferation and promotes homotypic cell adhe-
sion through a tyrosine kinase-dependent pathway [33].
Heterologous expression of EYFP–mouse capucin fusion
proteins in mammalian cell lines indicated a cis-Golgi
localization. Proteome analysis of Golgi fractions has indeed
revealed that many Golgi proteins remain to be identified [34].
In addition to its crucial role in membrane trafficking and
posttranslational modifications, the Golgi apparatus has been
implicated in signal transduction. As an illustration, a signaling
pathway involving a Golgi-associated Ras protein has recently
been discovered [35].
The high regional specificity of capucin expression suggests
an important role in striatal function and pathophysiology. To
test this hypothesis, we quantified capucin mRNA levels in two
models of Huntington disease: the widely studied R6/2
transgenic mice [25] and a recently developed model resting
on infected primary neuronal cultures [26]. In both cases, we
observed a highly significant down-regulation of capucin
expression. Strikingly, a number of transcripts reported to be
down-regulated in R6/2 mice [36,37] are actually striatal
markers (e.g., DARPP-32, preproenkephalin 1, ST8 a-N-
acetyl-neuraminide a-2,8-sialyltransferase 3, adenylate cyclase
5, D2 dopamine receptor) [17]. Since expression data are
collected before any degenerating neurons can be detected [38],
this observation suggests that striatal function might be
specifically targeted in early Huntington disease through the
impairment of a regulatory mechanism common to several
striatum-enriched species.
Materials and methods
Tissue sampling
For cDNA library construction and tissue distribution analysis of capucin
mRNAs, 9-to 10-week-old male C57BL/6 mice (Charles River Laboratories,
Les Oncins, France) were deeply anesthetized by intraperitoneal injection of
sodium pentobarbital (180 Ag per gram of body weight). After decapitation, the
brains were immediately removed, and all subsequent steps were carried out on
ice. The motor, cingulate, and somatosensory cortices; hippocampus; caudate–
putamen; nucleus accumbens; and thalamus were scalpel-dissected from 1-mm-
thick fresh brain slices cut in a coronal matrix (Pelco International, Redding,
CA, USA). The orbital, prelimbic, and entorhinal cortices and the substantia
nigra were scalpel-dissected from 0.3-mm-thick fresh brain coronal slices cut
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ventral tegmental area was sampled from 0.3-mm-thick coronal slices using a
0.53-mm diameter punch (Stoelting, Wood Dale, IL, USA). All dissections
were performed under stereomicroscopic observation with reference to a mouse
brain atlas [39]. Samples from the same brain region were pooled and Dounce-
homogenized in the appropriate lysis buffer.
To study the regulation of capucin mRNA expression, two rodent models of
Huntington disease were studied. The mouse model consisted of 6-week-old
R6/2 animals and their corresponding controls [8]. Striata were processed for
total RNA extraction as described [8]. The rat model consisted of primary cell
cultures generated from E16 ganglionic eminences. The cells were infected
with lentiviral constructs 24 h after plating, and total RNAs were extracted
8 weeks later as described [26].
cDNA cloning
Five micrograms of poly(A)+RNAs isolated from mouse caudate–putamen
with Dynabeads mRNA Direct kit (Dynal Biotech, Oslo, Norway) was used for
the construction of a ZAP Express library enriched with high-molecular-weight
cDNAs (Stratagene, La Jolla, CA, USA). One hundred thousand particle-
forming units of the amplified library were screened with a capucin-specific
oligonucleotide probe (Fig. 1; probe sequence 5V-CAGAGTCAGAAAGAG-
CAAGAGATGGCTGGGGC-3V). Hybridizations were carried out at 50-C in
Rapid-Hyb buffer (Amersham Biosciences, Little Chalfont, UK) containing
100 Ag/ml poly(A) and 250 fmol/ml (approximately 5  106 cpm/ml) probe 3V-
end-labeled with [a-32P]dATP using terminal deoxynucleotidyl transferase.
Four positive clones were obtained and excised into pBK-CMV phagemid. One
insert corresponded to the capucin long transcript variant, two to the capucin
short transcript variant, and one was chimeric.
Sequence alignments
The 5V and 3V ends of mouse capucin transcripts were determined by
assembling the cDNA sequences AY993933 and AY993934 with UniGene
cluster Mm.152484 ESTs. The resulting sequences were aligned with the
mouse genome to describe the structure of the mouse capucin gene and with
GenBank human and rat nonredundant and EST sequences to find orthologs of
mouse capucin. All nucleic sequence alignments were performed using the
BLAST algorithm [40].
The UniProt curated protein database was searched for capucin homologs
using BLAST. Protein sequence alignments were generated by the CLUSTAL
W program [41]. Transmembrane domains were predicted using the TMHMM
method [42].
Real-time quantitative RT-PCR
A 107-or 158-bp fragment was amplified from mouse or rat capucin,
respectively. PCR was carried out in a 25-Al reaction volume containing
Platinum SYBR Green qPCR SuperMix-UDG (Invitrogen, Carlsbad, CA,
USA), 10 AM each forward (mouse, 5V-GCAGGAGCATCCAGGAAGGA-
GAAAG-3V; rat, 5V-CCCACCTCCACAGACCCT-3V) and reverse (mouse, 5V-
GTGGGGCAGCTGCTCACAATGT-3V; rat, 5V-CCGATACCAAGCCTCCAC-
3V) primers, and 0.5% random-primed cDNA generated from 200 ng of total
RNA. An ABI Prism 7000 thermal cycler (Applied Biosystems, Foster City,
CA, USA) was programmed for an initial denaturation step (95-C, 2 min)
followed by 40 amplification cycles (95-C for 15 s, 60-C for 1 min).
Expression differences were calculated using the amplification rate of the target
as evaluated from serial dilutions of whole-brain cDNA and corrected for
differences in cDNA input by reference to the expression level of peptidyl-
propyl isomerase A, assumed to be constant throughout the brain.
The tissue distribution analysis was carried out on two replicates of each
sample. For Huntington disease models, triplicate samples were analyzed. The
mouse model consisted of four R6/2 mice and four wild-type controls; the rat
model of three independent mutant-infected and three control-infected cell
cultures. Differences between control and experimental samples were
calculated using the 2DDC t method [43]. Significance was assessed using
unpaired Student_s t test.In situ hybridization
T7 (antisense probe) or T3 (sense probe) in vitro transcription was carried
out in the presence of 0.5 mM rATP, rCTP, and rGTP; 0.325 mM rUTP; 0.175
mM digoxigenin-11–UTP (Roche Diagnostics, Mannheim, Germany); and
approximately 200 ng of a 1135-bp-long fragment amplified from the mouse
capucin coding sequence and 3V-UTR using T3-linked forward (5V-
ATTAACCCTCACTAAAGGGAGATCGGTCAAAGAGCCCAAAGC-3V)
and T7-linked reverse (5V-TAATACGACTCACTATAGGGGATCAACC-
TGCCCTCATTACAGAGC-3V) primers.
After removal, brains were immediately snap-frozen in isopentane at45-C
and stored at80-C. Twenty-micrometer-thick sections were cut in a CM3050S
cryostat (Leica Microsystems, Wetzlar, Germany) and mounted on SuperFrost
Plus slides (Menzel-Gla¨ser, Brunswick, Germany). After thawing, sections were
fixed in 4% paraformaldehyde for 20 min, rinsed in PBS, and then overlaid with
the hybridization solution (195 mM NaCl, 10 mM Tris–HCl, pH 7.5, 5.8 mM
Na2HPO4, 4.2 mM NaH2PO4, 5 mM EDTA, 50% formamide, 10% dextran
sulfate, 1mg/ml yeast tRNA, 1Denhardt_s), containing one-tenth of the in vitro
transcription reaction per 100 Al of solution. Following overnight incubation at
68-C, sections were washed at 65-C for 90 min in two changes of a solution of
1 SSC, 50% formamide, and 0.1%Tween 20. Immunodetection was performed
overnight at 4-C in TBS supplemented with 0.1% Tween 20, 0.5% gelatin, and
20% normal goat serum, using a 1:1000 dilution of alkaline phosphatase-
conjugated Fab fragments (Roche Diagnostics). After extensive washing, slides
were transferred into a dark vat filled with a mixture prepared by adding 18 Al of
NBT/BCIP stock solution (Roche Diagnostics) per milliliter of a solution of 100
mMNaCl, 100 mM Tris–HCl, pH 9.5, 50 mMMgCl2, 0.1% Tween 20, and 500
Ag/ml levamisole. Incubation was continued at room temperature until staining
developed. Sections were then counterstained with nuclear fast red (DAKO,
Glostrup, Denmark). Negative controls were provided by hybridizing with the
sense probe or omitting Fab fragments.
Heterologous expression experiments
Mouse capucin coding sequence was subcloned in frame with EYFP into
pEYFP-C1 and pEYFP-N1 CMV-driven mammalian expression vectors (BD
Biosciences, Mountain View, CA, USA). An 11-amino-acid-long spacer was
inserted between the carboxy-terminus of EYFP and the amino-terminus of
capucin, and a 6-amino-acid-long spacer was added between the carboxy-
terminus of capucin and the amino-terminus of EYFP. HeLa cells were grown in
Dulbecco_s modified Eagle medium (DMEM) supplemented with 4.5 g/L d-
glucose, 25 mMHepes, l-glutamine, and 10% decomplemented fetal calf serum.
CHO cells were grown in DMEM/Ham_s F12 (1:1) medium supplemented with
15 mM Hepes, l-glutamine, pyridoxine–HCl, and 10% decomplemented fetal
calf serum. All culture media were purchased from Invitrogen. Transfections
were performed with 300 ng of column-purified plasmid and 0.5 Al of
Lipofectamine 2000 reagent (Invitrogen) per square centimeter, and heterologous
expression was allowed to proceed overnight. If required, cells were subse-
quently incubatedwith 5 Ag/ml BFA for 4 h. For colocalization experiments, cells
were cotransfected with a plasmid encoding HA-tagged human unc-50 homolog
(pEM2) [23]. The HA-tagged protein was detected using a 1:1000 dilution of
HA.11 (Covance Research Products, Berkeley, CA, USA) as primary antibody
and a 1:100 dilution of Alexa Fluor 594 goat anti-mouse IgG (Invitrogen) as
secondary antibody. All observations were made with a confocal Axiovert 200M
microscope (Carl Zeiss, Go¨ttingen, Germany).
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